In this study, we demonstrated that when Capto MMC ImpRes chromatography is conducted under weak partitioning mode, high throughput, good yield, and effective byproduct removal are simultaneously achieved.īispecific antibody (bsAb) Capto MMC ImpRes Light chain (LC)-missing byproduct Mixed-mode chromatography Weak partitioning mode WuXiBody.Ĭopyright © 2021 Elsevier Inc. However, the dynamic binding capacity (DBC) of Capto MMC ImpRes is relatively low under the selected condition, making the process less desirable for large-scale manufacturing. In this work, with two concrete cases (WuXiBodies with asymmetric and symmetric designs, respectively), we showed that Capto MMC ImpRes mixed-mode chromatography can effectively remove. We previously showed that Capto MMC ImpRes mixed-mode chromatography under bind-elute mode can effectively remove this LC-missing species. Determination of SBC SBC was determined in 6 L PreDictor 96-well filter plates. While for bsAbs based on other platforms removal of such byproduct can pose considerable challenge to the downstream team, in this case WuXiBody's unique design makes separation relatively straightforward. Characteristics of the two antibodies used in the study 1 DBC at 10 breakthrough (DBC 10) for various antibodies measured at 4 min residence time. For purifying a WuXiBody-based symmetric bsAb, we identified a LC-missing species as a major byproduct. Cytiva Capto MMC ImpRes, 25mL, 40um Particle Size, 60 to 90mg Mab mL Binding Capacity, High-flow Agarose Matrix, Multimodal Weak Cation Exchanger Ligand. Capto MMC ImpRes is a mixed-mode resin based on the same ligand as that of Capto MMC, which possesses cation exchange and hydrophobic moieties, but has reduced bead size and ligand density, and hence offers improved resolution 4,5.
BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. Its key feature is the replacement of one parental antibody's CH1/CL region with the T cell receptor (TCR) constant domain, a design that promotes cognate heavy chain (HC)-light chain (LC) pairing. WuXiBody is a bispecific antibody (bsAb) platform developed by WuXi Biologics.
0 kommentar(er)
